Tian-Qi Du1, Xiang Li1, Wei-Si Zhong1, Jian-Dong Tian1, Yu-Xia Zhao2, Dan Liu3. 1. Department of Radiation Oncology, Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. 2. Department of Radiation Oncology, Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. zyx_yd@163.com. 3. Department of Radiation Oncology, Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China. unbbuem@163.com.
Abstract
PURPOSE: Radiotherapy is the mainstay for treating brain metastasis (BM). The objective of this study is to evaluate the overall survival (OS) of patients with BM of lung cancer treated with different radiotherapy modalities. METHODS: Patients with BM of lung cancer who underwent radiotherapy between July 2007 and November 2017 were collected, and their baseline demographics, clinicopathological characteristics and treatments were recorded. Survival was estimated by the Kaplan-Meier method and compared by using the log-rank test. Univariate and multivariate analysis of the prognostic factors were performed using the Cox proportional hazard regression model. RESULTS: A total of 144 patients were enrolled, of whom 77 underwent whole-brain radiotherapy (WBRT), 39 underwent whole brain radiotherapy with consecutive boost (WBRT + boost), and 28 underwent integrated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT). The OS in SIB-IMRT group was significantly longer than that in WBRT group (median OS 14 (95% confidence interval [CI] 8.8-19.1) vs.7 (95% CI 5.5-8.5) months, log-rank p < 0.001) and WBRT + boost group (median OS: 14 (95% CI 8.8-19.1) vs.11 (95% CI 8.3-13.7) months, log-rank p = 0.037). Multivariable analysis showed that mortality risk of patients treated with SIB-IMRT decrease by 56, 59, 64 and 64% in unadjusted model (hazard ratio [HR] = 0.44; 95% CI 0.28-0.70, p < 0.001), model 1 (HR = 0.41; 95% CI 0.26-0.65, p < 0.001), model 2 (HR = 0.36; 95% CI 0.21-0.61, p < 0.001), and model 3 (HR = 0.36; 95% CI 0.21-0.61, p < 0.001). CONCLUSIONS: For patients with BM of lung cancer, SIB-IMRT seems to be associated with a more favorable prognosis.
PURPOSE: Radiotherapy is the mainstay for treating brain metastasis (BM). The objective of this study is to evaluate the overall survival (OS) of patients with BM of lung cancer treated with different radiotherapy modalities. METHODS:Patients with BM of lung cancer who underwent radiotherapy between July 2007 and November 2017 were collected, and their baseline demographics, clinicopathological characteristics and treatments were recorded. Survival was estimated by the Kaplan-Meier method and compared by using the log-rank test. Univariate and multivariate analysis of the prognostic factors were performed using the Cox proportional hazard regression model. RESULTS: A total of 144 patients were enrolled, of whom 77 underwent whole-brain radiotherapy (WBRT), 39 underwent whole brain radiotherapy with consecutive boost (WBRT + boost), and 28 underwent integrated simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT). The OS in SIB-IMRT group was significantly longer than that in WBRT group (median OS 14 (95% confidence interval [CI] 8.8-19.1) vs.7 (95% CI 5.5-8.5) months, log-rank p < 0.001) and WBRT + boost group (median OS: 14 (95% CI 8.8-19.1) vs.11 (95% CI 8.3-13.7) months, log-rank p = 0.037). Multivariable analysis showed that mortality risk of patients treated with SIB-IMRT decrease by 56, 59, 64 and 64% in unadjusted model (hazard ratio [HR] = 0.44; 95% CI 0.28-0.70, p < 0.001), model 1 (HR = 0.41; 95% CI 0.26-0.65, p < 0.001), model 2 (HR = 0.36; 95% CI 0.21-0.61, p < 0.001), and model 3 (HR = 0.36; 95% CI 0.21-0.61, p < 0.001). CONCLUSIONS: For patients with BM of lung cancer, SIB-IMRT seems to be associated with a more favorable prognosis.
Authors: Philipp Lohmann; Norbert Galldiks; Martin Kocher; Alexander Heinzel; Christian P Filss; Carina Stegmayr; Felix M Mottaghy; Gereon R Fink; N Jon Shah; Karl-Josef Langen Journal: Methods Date: 2020-06-06 Impact factor: 3.608
Authors: T Iuchi; M Shingyoji; T Sakaida; K Hatano; O Nagano; M Itakura; H Kageyama; S Yokoi; Y Hasegawa; K Kawasaki; T Iizasa Journal: Lung Cancer Date: 2013-08-28 Impact factor: 5.705
Authors: Y-L Wu; C Zhou; C-K Liam; G Wu; X Liu; Z Zhong; S Lu; Y Cheng; B Han; L Chen; C Huang; S Qin; Y Zhu; H Pan; H Liang; E Li; G Jiang; S H How; M C L Fernando; Y Zhang; F Xia; Y Zuo Journal: Ann Oncol Date: 2015-06-23 Impact factor: 32.976
Authors: Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou Journal: N Engl J Med Date: 2016-12-06 Impact factor: 91.245
Authors: Darren A E Cross; Susan E Ashton; Serban Ghiorghiu; Cath Eberlein; Caroline A Nebhan; Paula J Spitzler; Jonathon P Orme; M Raymond V Finlay; Richard A Ward; Martine J Mellor; Gareth Hughes; Amar Rahi; Vivien N Jacobs; Monica Red Brewer; Eiki Ichihara; Jing Sun; Hailing Jin; Peter Ballard; Katherine Al-Kadhimi; Rachel Rowlinson; Teresa Klinowska; Graham H P Richmond; Mireille Cantarini; Dong-Wan Kim; Malcolm R Ranson; William Pao Journal: Cancer Discov Date: 2014-06-03 Impact factor: 39.397
Authors: Philipp Lohmann; Martin Kocher; Maximillian I Ruge; Veerle Visser-Vandewalle; N Jon Shah; Gereon R Fink; Karl-Josef Langen; Norbert Galldiks Journal: Front Neurol Date: 2020-02-07 Impact factor: 4.003
Authors: Shreya Chawla; Ishaan A Tewarie; Qingwei O Zhang; Alexander F C Hulsbergen; Rania A Mekary; Marike L D Broekman Journal: Neurosurg Rev Date: 2022-07-14 Impact factor: 2.800